Cytori Therapeutics (CYTX) Reports In-Line Q1 Loss of 7c/Share

Cytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $2.44 million.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'